Advancing Cancer Research Through Precision In Vitro Science
Bluegrass Oncology Advancements LLC conducts rigorous non-clinical research using established human cancer cell lines to evaluate the anticancer potential of public-domain compounds and novel research molecules. No human subjects. No animal models.
In Vitro Only
All research conducted exclusively in cell culture systems — no human or animal subjects involved at any stage.
Established Cell Lines
Utilization of validated, authenticated human cancer cell lines from recognized repositories including ATCC.
Drug Repurposing Program
Systematic evaluation of public-domain and off-patent compounds for previously uncharacterized anticancer activity.
Novel Molecules Pipeline
Synthesis and biological evaluation of proprietary research compounds designed for targeted oncological activity.
Rigorous Methodology. Transparent Science.
Bluegrass Oncology Advancements LLC operates at the intersection of pharmacology, cell biology, and translational oncology research. Our laboratory program is built on the systematic application of validated in vitro assay platforms to interrogate the biological activity of both established and novel chemical entities against well-characterized human cancer cell line models.
Our research philosophy prioritizes reproducibility, methodological rigor, and scientific transparency. All experimental data are generated using standardized protocols, authenticated cell lines, and validated analytical instruments. We adhere to the highest standards of laboratory practice in all aspects of our research operations.
Research Capabilities
- Cytotoxicity and antiproliferative activity assessment (MTT, SRB, CellTiter-Glo)
- Apoptosis induction and cell cycle perturbation analysis
- IC₅₀ determination and dose-response modeling
- Selectivity index evaluation against non-malignant reference lines
- Mechanistic pathway interrogation via Western blot and flow cytometry
- Combination index analysis for synergistic compound interactions
Validated Human Cancer Cell Line Models
MCF-7 / MDA-MB-231
Luminal A (MCF-7) and triple-negative (MDA-MB-231) breast cancer models representing distinct molecular subtypes for comparative evaluation.
Learn More →HCT116 / SW480
Microsatellite-unstable (HCT116) and chromosomally-unstable (SW480) colorectal models enabling evaluation across distinct mutational backgrounds.
Learn More →A549
KRAS-mutant lung adenocarcinoma model widely employed for evaluation of compounds targeting RAS-driven oncogenic signaling.
Learn More →HL-60 / K562
Acute promyelocytic leukemia (HL-60) and chronic myelogenous leukemia (K562) models for evaluation of hematologic anticancer activity.
Learn More →Drug Repurposing Program
Our drug repurposing initiative systematically evaluates public-domain, off-patent, and investigational compounds for previously uncharacterized or underexplored anticancer activity. By applying contemporary in vitro assay platforms to established pharmacological agents, we identify candidates with potential for repositioning into oncological applications.
View Repurposing Program →Novel Molecules Program
Our novel molecules program encompasses the design, synthesis, and biological evaluation of proprietary research compounds. Guided by structure-activity relationship analysis and target-based rationale, we develop chemical entities with defined mechanistic hypotheses and evaluate their anticancer potential across our validated cell line panel.
View Novel Molecules →Antiproliferative Activity of Repurposed Antifungal Agents Against Triple-Negative Breast Cancer Cell Lines: An In Vitro Evaluation
Journal of Experimental Oncology Research · 2024
Systematic evaluation of azole-class antifungal compounds against MDA-MB-231 and MCF-7 cell lines revealed selective cytotoxic activity with IC₅₀ values in the low micromolar range, warranting further mechanistic investigation.
Structure-Activity Relationships of Novel Benzimidazole Derivatives as Potential Anticancer Agents: In Vitro Cytotoxicity and Apoptosis Studies
Bioorganic & Medicinal Chemistry Letters · 2024
A series of 2-substituted benzimidazole derivatives were synthesized and evaluated for cytotoxic activity against a panel of human cancer cell lines. Lead compounds demonstrated sub-micromolar IC₅₀ values and induced apoptosis via the intrinsic mitochondrial pathway.
Combination Index Analysis of Metformin and Doxorubicin in HCT116 Colorectal Carcinoma Cells: Synergistic Antiproliferative Effects
Cancer Cell Biology Reports · 2023
Isobolographic analysis demonstrated synergistic antiproliferative effects when metformin was combined with sub-therapeutic doxorubicin concentrations in HCT116 cells, with combination index values below 0.8 across multiple effect levels.
No Human Subjects. No Animal Models. Rigorous In Vitro Science.
Bluegrass Oncology Advancements LLC is committed to the highest standards of ethical and scientifically rigorous non-clinical research. All experimental work is conducted exclusively in validated in vitro cell culture systems. Our research program does not involve human subjects, animal models, or any procedures requiring institutional animal care and use committee (IACUC) oversight. This commitment to purely in vitro methodology reflects both our scientific focus and our ethical framework.
Partner With Our Research Team
We welcome inquiries from academic institutions, pharmaceutical companies, and independent researchers interested in collaborative research programs, contract research services, or scientific exchange. Our team is available to discuss research objectives, methodological approaches, and potential areas of mutual scientific interest.
We welcome inquiries from academic and industry research partners.
Submit a Research Inquiry